NDAINHALATIONGAS
Approved
Jun 2013
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
MEDICAL AIR, USP (medical air) by Advanced Solutions Life Sciences. Approved for idiopathic pulmonary fibrosis. First approved in 2013.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEDICAL AIR, USP is a gas-based inhalation therapy approved by the FDA in June 2013 for treating Idiopathic Pulmonary Fibrosis (IPF). As a non-pharmacological medical gas product, it delivers therapeutic air via inhalation to IPF patients. The product represents a unique modality in the fibrosis treatment landscape with a mechanism distinct from small-molecule antifibrotics.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30%), indicating mature market positioning and stable but potentially constrained team growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on MEDICAL AIR, USP at Advanced Solutions Life Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.